Preferred Label : Saracatinib;
NCIt synonyms : SRC Kinase Inhibitor AZD0530; 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-; N-(5-Chloro-1,3-Benzodioxol-4-Yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-((Oxan-4-yl)Oxy)Quinazolin-4-Amine;
NCIt related terms : AZD0530;
NCIt definition : An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor
activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine
kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds
to and inhibits these tyrosine kinases and affects cell motility, cell migration,
adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib
inhibits Src kinase-mediated osteoclast bone resorption.;
Alternative definition : NCI-GLOSS: A substance being studied in the treatment of some types of cancer. AZD0530
blocks enzymes needed for cancer growth. It is a type of tyrosine kinase inhibitor.;
UNII : 9KD24QGH76;
InChIKey : OUKYUETWWIPKQR-UHFFFAOYSA-N;
CAS number : 379231-04-6;
Molecule name : AZD0530;
Chemical formula : C27H32ClN5O5;
NSC code : 735464;
Codes from synonyms : CDR0000532132;
Origin ID : C48378;
UMLS CUI : C2828242;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_affects_gene_product
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_salt_form
- has_target
- is_free_acid_or_base_form_of
